{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:53:18Z","timestamp":1772121198773,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NYU Cancer Center","award":["5P30CA16087"],"award-info":[{"award-number":["5P30CA16087"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.leukres.2016.11.015","type":"journal-article","created":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T14:12:11Z","timestamp":1480515131000},"page":"13-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera\/essential thrombocythemia myelofibrosis (post-PV\/ET MF)"],"prefix":"10.1016","volume":"53","author":[{"given":"John","family":"Mascarenhas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lonette","family":"Sandy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie","family":"Newsom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vesna","family":"Najfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsivia","family":"Hochman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith D.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.leukres.2016.11.015_bib0005","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.2012.42.0240","article-title":"Improving survival trends in primary myelofibrosis: an international study","volume":"30","author":"Cervantes","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.leukres.2016.11.015_bib0010","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.leukres.2016.11.015_bib0015","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.leukres.2016.11.015_bib0020","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","article-title":"The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis","volume":"126","author":"Deininger","year":"2015","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.leukres.2016.11.015_bib0025","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3182.3182","article-title":"Ruxolitinib-induced modulation of bone marrow microenvironment in patients with myelofibrosis is associated with inflammatory cytokine levels","volume":"124","author":"Kvasnicka","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.11.015_bib0030","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/asheducation-2015.1.329","article-title":"Looking forward: novel therapeutic approaches in chronic and advanced phases of myelofibrosis","volume":"2015","author":"Mascarenhas","year":"2015","journal-title":"Hematology"},{"issue":"5","key":"10.1016\/j.leukres.2016.11.015_bib0035","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.bcp.2007.04.007","article-title":"HDAC inhibitors: clinical update and mechanism-based potential","volume":"74","author":"Glaser","year":"2007","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.leukres.2016.11.015_bib0040","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08266.x","article-title":"A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms","volume":"150","author":"Rambaldi","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.leukres.2016.11.015_bib0045","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.leukres.2012.03.003","article-title":"Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis","volume":"36","author":"Quintas-Cardama","year":"2012","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.leukres.2016.11.015_bib0050","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/bjh.12220","article-title":"A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera\/essential thrombocythaemia myelofibrosis (post-PV\/ET MF)","volume":"161","author":"Mascarenhas","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.leukres.2016.11.015_bib0055","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/bjh.12384","article-title":"Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis","volume":"162","author":"DeAngelo","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2016.11.015_bib0060","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3109\/10428194.2013.805329","article-title":"Anti-transforming growth factor-beta therapy in patients with myelofibrosis","volume":"55","author":"Mascarenhas","year":"2014","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"10.1016\/j.leukres.2016.11.015_bib0065","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","article-title":"International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for myelofibrosis research and treatment (IWG-MRT)","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2016.11.015_bib0070","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2016.11.015_bib0075","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.leukres.2016.11.015_bib0080","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.leukres.2016.11.015_bib0085","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.1158\/1078-0432.CCR-13-0905","article-title":"JAK1\/2 and pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease","volume":"19","author":"Evrot","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"21","key":"10.1016\/j.leukres.2016.11.015_bib0090","first-page":"711","article-title":"Efficacy, safety, and confirmation of the recommended phase 2 starting dose of the combination of ruxolitinib (RUX) and panobinostat (PAN) in patients (Pts) with myelofibrosis (MF)","volume":"124","author":"Harrison","year":"2015","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616302612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616302612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T18:16:18Z","timestamp":1718907378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212616302612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":18,"alternative-id":["S0145212616302612"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2016.11.015","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727086783.793541456","asserted-by":"object"}]},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera\/essential thrombocythemia myelofibrosis (post-PV\/ET MF)","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2016.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}